{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:46:15Z","timestamp":1792089975787,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00520-026-11223-7","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:40:50Z","timestamp":1790138450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world use of G-CSF primary prophylaxis in small cell lung cancer: secondary data analysis from the French national cohorts KBP-2020-CPHG and ESCAP-2020-CPHG"],"prefix":"10.1007","volume":"34","author":[{"given":"L.","family":"Falchero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Scott\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Couraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Menia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Debieuvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"Supplement 5","key":"11223_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K et al (2016) Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 27(Supplement 5):111\u2013118","journal-title":"Ann Oncol"},{"issue":"47","key":"11223_CR2","first-page":"8","volume":"2011","author":"MS Aapro","year":"2010","unstructured":"Aapro MS, Bohlius J, Cameron DA et al (2010) update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. EJC 2011(47):8\u201332","journal-title":"EJC"},{"key":"11223_CR3","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33:3199\u20133212","journal-title":"J Clin Oncol"},{"issue":"1","key":"11223_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JOP.18.00269","volume":"15","author":"AJ Zimmer","year":"2019","unstructured":"Zimmer AJ, Freifeld AG (2019Jan) Optimal Management of Neutropenic Fever in Patients With Cancer. J Oncol Pract 15(1):19\u201324. https:\/\/doi.org\/10.1200\/JOP.18.00269.","journal-title":"J Oncol Pract"},{"issue":"2","key":"11223_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","volume":"6","author":"J Crawford","year":"2008","unstructured":"Crawford J, Dale DC, Kuderer NM et al (2008Feb) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 6(2):109\u2013118. https:\/\/doi.org\/10.6004\/jnccn.2008.0012","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"11223_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-024-08817-4","volume":"32","author":"O Rohr","year":"2024","unstructured":"Rohr O, Priou S, Chatellier G et al (2024) Prevalence and risks of intravenous chemotherapy-induced severe neutropenia in solid cancers: a multicenter retrospective cohort study on real-life data. Support Care Cancer 32(10):657. https:\/\/doi.org\/10.1007\/s00520-024-08817-4","journal-title":"Support Care Cancer"},{"issue":"9","key":"11223_CR7","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1002\/cam4.2955","volume":"9","author":"T Aagaard","year":"2020","unstructured":"Aagaard T, Reekie J, J\u00f8rgensen M et al (2020) Mortality and admission to intensive care units after febrile neutropenia in patients with cancer. Cancer Med 9(9):3033\u20133042. https:\/\/doi.org\/10.1002\/cam4.2955","journal-title":"Cancer Med"},{"key":"11223_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01312-y","volume":"20","author":"MY Li","year":"2021","unstructured":"Li MY, Liu LZ, Dong M et al (2021) Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis. Mol Cancer 20:22","journal-title":"Mol Cancer"},{"issue":"21","key":"11223_CR9","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.2025.0560","volume":"333","author":"SY Kim","year":"2025","unstructured":"Kim SY, Park SH, Chiang AC, Park HS (2025) Small cell lung cancer: a review. JAMA 333(21):1906\u20131917","journal-title":"JAMA"},{"key":"11223_CR10","doi-asserted-by":"publisher","unstructured":"Debieuvre D, Molinier O, Falchero L, Study Group KBP-2020-CPHG, KBP-2020-CPHG et al (2020) Lung cancer trends and tumor characteristic changes over 20 years (2000\u20132020): results of three French consecutive nationwide prospective cohorts\u2019 studies. Lancet Reg Health Eur 22:100492. https:\/\/doi.org\/10.1016\/j.lanepe.2022.100492","DOI":"10.1016\/j.lanepe.2022.100492"},{"key":"11223_CR11","doi-asserted-by":"publisher","unstructured":"Pirker R (2020) Conquering lung cancer: current status and prospects for the future. Pulmonol 26(5):283\u2013290. https:\/\/doi.org\/10.1016\/j.pulmoe.2020.02.005","DOI":"10.1016\/j.pulmoe.2020.02.005"},{"issue":"6","key":"11223_CR12","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s00280-017-3324-7","volume":"79","author":"T Fujiwara","year":"2017","unstructured":"Fujiwara T, Kenmotsu H, Naito T et al (2017) The incidence and risk factors of febrile neutropenia in chemotherapy-na\u00efve lung cancer patients receiving etoposide plus platinum. Cancer Chemother Pharmacol 79(6):1229\u20131237","journal-title":"Cancer Chemother Pharmacol"},{"key":"11223_CR13","unstructured":"R\u00e9f\u00e9rentiel Auvergne-Rhone-Alpes Oncologie thoracique- AURA- soins de support- 13 \u00e8me \u00e9dition Etienne-Mastro\u00efanni B, Avrillon V, Fontaine-Delaruelle C, Paulus V, Pierret T on behalf of the editing committee of Auvergne Rh\u00f4ne-Alpes Guidelines in Thoracic Oncology. [Guidelines on Supportive Care in Lung Cancers: 2025 Update]. ARISTOT; 2025 [French], Available from http:\/\/referentiels-aristot.com\/.\u00a0Accessed 14 Jun 2026"},{"issue":"7","key":"11223_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1159\/000535822","volume":"102","author":"M Takahashi","year":"2024","unstructured":"Takahashi M, Takahashi K, Kaneda H et al (2024) Analysis of risk factors for febrile neutropenia in patients with small-cell lung cancer receiving carboplatin plus etoposide therapy. Oncology (Williston Park) 102(7):565\u2013573. https:\/\/doi.org\/10.1159\/000535822","journal-title":"Oncology (Williston Park)"},{"key":"11223_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114277","volume":"210","author":"L Falchero","year":"2024","unstructured":"Falchero L, Meyer N, Molinier O et al (2024) Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: impact of immunotherapy on overall survival in a real-life setting. Eur J Cancer 210:114277. https:\/\/doi.org\/10.1016\/j.ejca.2024.114277","journal-title":"Eur J Cancer"},{"issue":"10212","key":"11223_CR16","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212):1929\u20131939. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6","journal-title":"Lancet"},{"key":"11223_CR17","doi-asserted-by":"publisher","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, IMpower133 Study Group et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379(23):2220\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa1809064","DOI":"10.1056\/NEJMoa1809064"},{"key":"11223_CR18","doi-asserted-by":"publisher","unstructured":"Lyman GH, Dale DC, Culakova E et al (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24(10):2475\u20132484. https:\/\/doi.org\/10.1093\/annonc\/mdt226","DOI":"10.1093\/annonc\/mdt226"},{"issue":"4","key":"11223_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10147-024-02469-4","volume":"29","author":"E Ichihara","year":"2022","unstructured":"Ichihara E, Ochi N, Makimoto G et al (2022) Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022. Int J Clin Oncol 29(4):355\u2013362. https:\/\/doi.org\/10.1007\/s10147-024-02469-4","journal-title":"Int J Clin Oncol"},{"key":"11223_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100493","volume":"29","author":"H Watanabe","year":"2021","unstructured":"Watanabe H, Karayama M, Yasui H et al (2021) Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide. Cancer Treat Res Commun 29:100493. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100493.","journal-title":"Cancer Treat Res Commun"},{"issue":"9","key":"11223_CR21","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/1759-7714.14811","volume":"14","author":"N Mamesaya","year":"2023","unstructured":"Mamesaya N, Kodama H, Iida Y et al (2023) Efficacy and safety of carboplatin and etoposide in older extensive-stage small-cell lung cancer patients with a poor performance status. Thorac Cancer 14(9):805\u2013814. https:\/\/doi.org\/10.1111\/1759-7714.14811","journal-title":"Thorac Cancer"},{"issue":"6","key":"11223_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-024-08524-0","volume":"32","author":"F Scott\u00e9","year":"2024","unstructured":"Scott\u00e9 F, Artru P, Saghatchian M et al (2024) Leveraging G-CSF prescribing in the outpatient setting: considerations beyond clinical factors-a questionnaire study. Support Care Cancer 32(6):347. https:\/\/doi.org\/10.1007\/s00520-024-08524-0","journal-title":"Support Care Cancer"},{"key":"11223_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2021-003082","author":"F Scotte","year":"2021","unstructured":"Scotte F, Simon H, Laplaige P et al (2021) Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experiment. BMJ Support Palliat Care. https:\/\/doi.org\/10.1136\/bmjspcare-2021-003082","journal-title":"BMJ Support Palliat Care"},{"issue":"2","key":"11223_CR24","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00520-019-04879-x","volume":"28","author":"E Aras","year":"2020","unstructured":"Aras E, Bayraktar-Ekincioglu A, Kilickap S (2020) Risk assessment of febrile neutropenia and evaluation of G-CSF use in patients with cancer: a real-life study. Support Care Cancer 28(2):691\u2013699. https:\/\/doi.org\/10.1007\/s00520-019-04879-x","journal-title":"Support Care Cancer"},{"issue":"12","key":"11223_CR25","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1080\/03007995.2022.2113693","volume":"38","author":"C Ge\u00dfner","year":"2022","unstructured":"Ge\u00dfner C, Fietz T, Losem C et al (2022) Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR. Curr Med Res Opin 38(12):2191\u20132199. https:\/\/doi.org\/10.1080\/03007995.2022.2113693","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"11223_CR26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.54482","volume":"16","author":"M Kaakoua","year":"2024","unstructured":"Kaakoua M, Boujmadi S, Belbaraka R et al (2024) The use of granulocyte colony-stimulating factor as primary prophylaxis in patients undergoing chemotherapy: an experience of Moroccan oncologists. Cureus 16(2):e54482. https:\/\/doi.org\/10.7759\/cureus.54482","journal-title":"Cureus"},{"key":"11223_CR27","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00508-023-02300-6","volume":"136","author":"P Gasc\u00f3n","year":"2024","unstructured":"Gasc\u00f3n P, Awada A, Karihtala P et al (2024) Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment. Wien Klin Wochenschr 136:362\u2013368","journal-title":"Wien Klin Wochenschr"},{"issue":"4","key":"11223_CR28","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00520-018-4481-x","volume":"27","author":"H Link","year":"2019","unstructured":"Link H, Kerkmann M, Holtmann L et al (2019) G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey. Support Care Cancer 27(4):1459\u20131469. https:\/\/doi.org\/10.1007\/s00520-018-4481-x. (Working Groups Supportive Care (ASORS now AGSMO) and Medical Oncology (AIO) within the German Cancer Society (DKG))","journal-title":"Support Care Cancer"},{"key":"11223_CR29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.lungcan.2021.01.025","volume":"153","author":"F Gomes","year":"2021","unstructured":"Gomes F, Faivre-Finn C, Mistry H et al (2021) Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial. Lung Cancer 153:165\u2013170. https:\/\/doi.org\/10.1016\/j.lungcan.2021.01.025.","journal-title":"Lung Cancer"},{"issue":"1","key":"11223_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09644-8","volume":"22","author":"C Wang","year":"2022","unstructured":"Wang C, Zhu S, Miao C et al (2022) Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial. BMC Cancer 22(1):542. https:\/\/doi.org\/10.1186\/s12885-022-09644-8","journal-title":"BMC Cancer"},{"issue":"3","key":"11223_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.12788\/jcso.0117","volume":"13","author":"JN Bernens","year":"2015","unstructured":"Bernens JN, Hartman K, Curley B et al (2015) Assessing the impact of a targeted electronic medical record intervention on the use of growth factor in cancer patients. J Community Support Oncol 13(3):113\u2013116. https:\/\/doi.org\/10.12788\/jcso.0117","journal-title":"J Community Support Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11223-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11223-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11223-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:48:16Z","timestamp":1792086496000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11223-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11223"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11223-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LF, FS, SC, DD received honoraria as members of the Scientific Committee of the Study. KM is a Chugai Pharma France employee. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1006"}}